Keywords: Ipsen, Oncodesign, LRRK2 kinase inhibitors, Parkinson's disease, Research collaboration

Ipsen and Oncodesign collaborate on Parkinson's disease target

Article | 05 January 2012

French companies Oncodesign and Ipsen (Euronext: IPN) have entered into a research collaboration to discover and develop innovative LRRK2 kinase ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Oncodesign

Ipsen

Go to company listing